Johnson & Johnson Spins Off DePuy Synthes Amid Pricing Pressure and Strategic Focus on High-Growth Markets

J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.